Clinical Report: Preservation of Vision in GA in ARCHER Trial Continues Evaluation in ARCHER II
Overview
The ARCHER trial evaluated ANX007 for geographic atrophy (GA) and demonstrated a significant reduction in vision loss compared to sham treatments, with a notable 15-letter loss reduction. The findings suggest a promising avenue for preserving visual acuity in GA patients, warranting further investigation in the upcoming phase 3 trial.
Background
Geographic atrophy (GA) is a progressive form of age-related macular degeneration (AMD) that leads to irreversible vision loss. Current treatments primarily focus on slowing lesion growth rather than preserving vision. The ARCHER trial's findings on ANX007 represent a potential shift in treatment goals towards maintaining visual acuity, which is crucial for patient quality of life.
Data Highlights
No numerical data available in the provided source material.
Key Findings
['ANX007 showed a significant reduction in 15-letter loss of vision compared to sham treatments in the ARCHER trial.', 'The number needed to treat (NNT) to prevent one patient from experiencing clinically significant vision loss was 7.', 'Patients receiving ANX007 monthly had a 5.6% rate of 15-letter loss, compared to 21.3% in the sham group.', 'The phase 3 ARCHER II trial will focus on visual acuity as a primary endpoint, a first for GA studies.', 'ANX007 is administered via intravitreal injection, similar to standard procedures.']Clinical Implications
The findings from the ARCHER trial suggest that ANX007 may provide a clinically meaningful option for preserving vision in GA patients. Clinicians should consider the potential benefits of ANX007 in their treatment discussions with patients, particularly in light of the favorable NNT compared to other common therapies.
Conclusion
The ARCHER trial results indicate a promising advancement in the treatment of geographic atrophy, with ANX007 showing potential for vision preservation. Continued evaluation in the phase 3 ARCHER II trial will be critical to confirm these findings.
References
- Retinal Physician, 2025 -- Archer Study Analysis
- Retinal Physician, 2024 -- New ARCHER ANX007 in GA Treatment Findings Presented at ARVO
- Retinal Physician, 2025 -- Video: Can Vonaprument Slow Vision Loss in GA?
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials - ScienceDirect
- Retinal Physician — Video: Can Vonaprument Slow Vision Loss in GA?
- Age-Related Macular Degeneration Preferred Practice Pattern® - Oregon Health & Science University
- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials - ScienceDirect
- Archer Study Analysis | Retinal Physician
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
